Hepatitis B virus related membranous glomerulonephritis and proteinuria treated with lamivudine and tenofovir

BMJ Case Reports

Volumn , Issue , 2011, Pages

  Das, Partha ^a   Vivek, Vadamalai ^b   Ford, Martin ^b   Kingdon, Edward ^b   Holt, Stephen ^c  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b Worthing Hospital   (United Kingdom)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; LAMIVUDINE; TENOFOVIR;

ABDOMINAL PAIN; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; DISEASE COURSE; DRUG TOLERABILITY; FLU LIKE SYNDROME; FOLLOW UP; FOOT EDEMA; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; HYPERTENSION; LIVER BIOPSY; LIVER FUNCTION TEST; LOW DRUG DOSE; MALE; MEMBRANOUS GLOMERULONEPHRITIS; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; VIRUS LOAD; VOMITING;

EID: 80053063458     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr.05.2011.4287     Document Type: Article

References (15)

1. Hepatitis B: factsheet WHO/204 . Geneva : World Health Organization, October 2000. http://www.who.int/mediacentre/factsheets/fs204/en (accessed 20 July 2011)
2. Combes B, Shorey J, Barrera A, et al. Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane. Lancet 1971;2:234-7.
3. Gilbert RD, Wiggelinkhuizen J. The clinical course of hepatitis B virusassociated nephropathy. Pediatr Nephrol 1994;8:11-14. (Pubitemid 24042358)
4. Lai KN, Li PK, Lui SF, et al. Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 1991;324:1457-63.
5. Gan SI, Devlin SM, Scott-Douglas NW, et al. Lamivudine for the treatment of membranous glomerulopathy secondary to chronic Hepatitis B infection. Can J Gastroenterol 2005;19:625-9. (Pubitemid 41723288)
6. Lin CY . Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon. Kidney Int 1995;47:225-30.
7. Al-Wakeel J, Mitwalli A, Tarif N, et al. Role of interferon-alpha in the treatment of primary glomerulonephritis. Am J Kidney Dis 1999;33:1142-6. (Pubitemid 29252686)
8. Tang S, Lai FM, Lui YH, et al. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int 2005;68:1750-8. (Pubitemid 43169919)
9. Chayama K, Suzuki Y, Kobayashi M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998;27:1711-16. (Pubitemid 28264699)
10. Khedmat H, Taheri S. Hepatitis B virus-associated nephropathy: an International Data Analysis. IJKD 2010;4:101-5.
11. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16. (Pubitemid 36245757)
12. Schildgen O, Sirma H, Funk A, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006;354:1807-12 .
13. Del Poggio P, Jamoletti C, Zaccanelli M. Tenofovir in chronic hepatitis B. Hepatology 2005;41:1199-200. (Pubitemid 40593931)
14. Van Bömmel F, Wünsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40:1421-5. (Pubitemid 39657017)
15. Gallant JE, Parish MA, Keruly JC, et al. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005;40:1194-8. (Pubitemid 40490248)